{"product_id":"michigan-medicine-advanced-genitourinary-malignancies-symposium-2025","title":"Michigan Medicine Advanced Genitourinary Malignancies Symposium 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eMichigan Medicine Advanced Genitourinary Malignancies Symposium 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 18 videos + 18 audios + 18 file sub vtt + 19 pdfs, size: 5.16 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: Physicians (Medical Oncologists, Urologists, Radiation Oncologists, Internists)\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003eThis one-day symposium is dedicated to the comprehensive management of genitourinary malignancies, including prostate, bladder, and kidney cancers. Hosted by the NCI-designated Rogel Cancer Center, the course emphasizes a transdisciplinary approach to reducing the cancer burden and advancing health equity. It serves as a critical update for clinicians, bridging the gap between cutting-edge research—such as novel biomarkers and cellular therapies—and standard clinical practice. The program highlights the University of Michigan’s role in leading groundbreaking clinical trials and refining standards of care for complex GU cases.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"3\"\u003e+ What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"4\"\u003eAttendees will be able to:\u003c\/p\u003e\n\u003cul data-path-to-node=\"5\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,0,0\"\u003eUnderstand\u003c\/b\u003e and apply the latest diagnostic modalities for the classification and risk-stratification of genitourinary cancers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,1,0\"\u003eAppreciate\u003c\/b\u003e the rapidly evolving therapeutic landscape, specifically the increasing use of targeted agents, immunomodulators, antibody-drug conjugates (ADCs), and cellular therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,2,0\"\u003eIdentify\u003c\/b\u003e impactful research findings that drive future diagnostic and prognostic strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,3,0\"\u003eNavigate\u003c\/b\u003e clinical nuances in managing “in-between” cases, such as localized prostate cancer with nodal PSMA avidity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,4,0\"\u003eEvaluate\u003c\/b\u003e the role of circulating tumor DNA (ctDNA) in risk-stratifying patients with Muscle-Invasive Bladder Cancer (MIBC).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"6\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"6\"\u003e+ Event Details\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"7\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,0,0\"\u003eDate:\u003c\/b\u003e Saturday, November 22, 2025\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,1,0\"\u003eTime:\u003c\/b\u003e 8:30 AM – 3:30 PM ET\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,2,0\"\u003eLocation:\u003c\/b\u003e The Sheraton Ann Arbor, 3200 Boardwalk Dr, Ann Arbor, Michigan\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"8\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"8\"\u003e+ Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"9\"\u003eThis course is designed for the interdisciplinary team involved in GU oncology:\u003c\/p\u003e\n\u003cul data-path-to-node=\"10\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,0,0\"\u003ePhysicians\u003c\/b\u003e (Medical Oncologists, Urologists, Radiation Oncologists, Internists)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,1,0\"\u003eHouse Officers\u003c\/b\u003e (Residents and Fellows)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,2,0\"\u003ePhysician Assistants\u003c\/b\u003e and Nurse Practitioners\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,3,0\"\u003eNurses\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,4,0\"\u003eOther Healthcare Professionals\u003c\/b\u003e involved in cancer care\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"11\"\u003e+ Why Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,0,0\"\u003eEmerging Therapies:\u003c\/b\u003e Gain specific insights into the “nuance” of using Antibody-Drug Conjugates (ADCs) in bladder cancer, moving beyond simple prescription to understanding toxicity and sequencing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,1,0\"\u003ePrecision Medicine:\u003c\/b\u003e Learn how new tools like PSMA PET and ctDNA are redefining “localized” versus “metastatic” disease, directly impacting treatment decisions for prostate and bladder cancer patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,2,0\"\u003eExpert Faculty:\u003c\/b\u003e Hear directly from Michigan Medicine leaders who are driving the research on SBRT for renal cell carcinoma and immunotherapy strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eImmunotherapy for Localized Bladder Cancer – Universal Strategy or Tailored Approach\u003c\/li\u003e\n\u003cli\u003eRisk Stratification in MIBC – The Emerging Role of ctDNA\u003c\/li\u003e\n\u003cli\u003eFrom Targets to Toxicity – Clinical Nuance in ADC Therapy for Bladder Cancer\u003c\/li\u003e\n\u003cli\u003eMetastatic Body Radiotherapy for Localized RCC – Emerging Evidence, Evolving Role\u003c\/li\u003e\n\u003cli\u003eChoosing Wisely – Patient Selection for Adjuvant IO in Kidney Cancer\u003c\/li\u003e\n\u003cli\u003eMetastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Sarah Elizabeth Yentz, MD)\u003c\/li\u003e\n\u003cli\u003eMetastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Udit Singhal, MD)\u003c\/li\u003e\n\u003cli\u003eManaging the ‘In-Between’ – Localized Prostate Cancer with Nodal PSMA Avidity\u003c\/li\u003e\n\u003cli\u003eWhen to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient\u003c\/li\u003e\n\u003cli\u003eWhen to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient\u003c\/li\u003e\n\u003cli\u003eWhen to Radiate – Managing the Primary and Metastases in Low-Volume Metastatic Castrate Sensitive Prostate Cancer\u003c\/li\u003e\n\u003cli\u003eTailoring Systemic Treatment in Low-volume mCSPC – How Long and What to Choose\u003c\/li\u003e\n\u003cli\u003eTo PET or Not – Deciding the Best Imaging for Metastatic Prostate Cancer\u003c\/li\u003e\n\u003cli\u003ePluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sarah Elizabeth Yentz, MD)\u003c\/li\u003e\n\u003cli\u003ePluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sean R. Miller, MD)\u003c\/li\u003e\n\u003cli\u003eBeyond Symptom Control The Evolving Role of Radiation in Metastatic Castrate Resistant Prostate Cancer\u003c\/li\u003e\n\u003cli\u003eGermline Testing in Prostate Cancer What the Oncologist Needs to Know\u003c\/li\u003e\n\u003cli\u003eNext Generation Sequencing in Metastatic Prostate Cancer When, Who, and Why\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954543628386,"sku":"MED-AMB05806","price":25.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Michigan-Medicine-Advanced-Genitourinary-Malignancies-Symposium-2025.jpg?v=1779379422","url":"https:\/\/meducourse.com\/products\/michigan-medicine-advanced-genitourinary-malignancies-symposium-2025","provider":"Meducourse","version":"1.0","type":"link"}